Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1196)	1/20/2000 8:48:00 AM
From: NeuroInvestment	Read Replies (1) \| Respond to of 2001

Rick; FWIW it's worth, my timeline would be: 1) With the Phase II ADD trial for Perceptin now underway, it would surprise me if they partner it before there is some data. The reason they went ahead with the trial was that the current offers were inadequate, and I doubt that Big Pharma is stepping up with suddenly enhanced offers when all their attention is on Merger talks. 2) Phase II Perceptin is underway--or at least patient enrollment was about to start several weeks ago, and I assume it has. 3) The marketing application in Japan will be submitted by end of 1H. 4) T/N PMA will be submitted later this quarter. 5) I would be surprised if distribution agreement for ADCON-P were to be signed soon, since the trial won't complete until the fall, PMA to be filed 4Q. So the answer is #2, the Perceptin trial. NeuroInvestment (www.neuroinvestment.com)